CTLA4 and glioblastoma: A preliminary study that induced prolonged survival in CD73 knockout models of GBM treated with dual blockade of PD-1 and CTLA-4 highlights the potential of CD73 for combination therapy and need for further investigation (Goswami et al., 2020).